Lv6
2356 积分 2024-05-23 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
3天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
3天前
已完结
Progress in outcomes for patients with metastatic squamous non-small-cell lung cancer
3天前
已关闭
Progress in outcomes for patients with metastatic squamous non-small-cell lung cancer
3天前
已完结
The immune system offers a window into aging
4天前
已完结
Restoring resident tissue macrophages to combat aging and cancer
4天前
已完结
Aging reshapes the adaptive immune system from healer to saboteur
4天前
已完结
Sustained immune youth risks autoimmune disease in the aging host
4天前
已完结
Immune surveillance of senescent cells in aging and disease
4天前
已完结
Metabolic regulation of immunological aging
4天前
已完结
皖公网安备34019202002308
